180 related articles for article (PubMed ID: 35899388)
1. Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.
Vangapandu HV; Jain N; Gandhi V
Expert Opin Investig Drugs; 2017 May; 26(5):625-632. PubMed ID: 28388280
[TBL] [Abstract][Full Text] [Related]
2. Duvelisib: A comprehensive profile.
Aljohar HI; Al-Abdullah E; Alzoman NZ; Darwish HW; Darwish IA
Profiles Drug Subst Excip Relat Methodol; 2024; 49():19-40. PubMed ID: 38423708
[TBL] [Abstract][Full Text] [Related]
3. Model-Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen.
Morcos PN; Moss J; Veasy J; Hiemeyer F; Childs BH; Garmann D
Clin Pharmacol Ther; 2024 May; 115(5):1092-1104. PubMed ID: 38226495
[TBL] [Abstract][Full Text] [Related]
4. A Long Way to Go: A Scenario for Clinical Trials of PI3K Inhibitors in Treating Cancer.
Trigueiros BAFDS; Santos IJS; Pimenta FP; Ávila AR
Cancer Control; 2024; 31():10732748241238047. PubMed ID: 38494880
[TBL] [Abstract][Full Text] [Related]
5. PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise.
Bou Zeid N; Yazbeck V
Blood Lymphat Cancer; 2023; 13():1-12. PubMed ID: 36919100
[TBL] [Abstract][Full Text] [Related]
6. Disrupting pro-survival and inflammatory pathways with dimethyl fumarate sensitizes chronic lymphocytic leukemia to cell death.
Mantione ME; Meloni M; Sana I; Bordini J; Del Nero M; Riba M; Ranghetti P; Perotta E; Ghia P; Scarfò L; Muzio M
Cell Death Dis; 2024 Mar; 15(3):224. PubMed ID: 38494482
[TBL] [Abstract][Full Text] [Related]
7. The Value of Neutrophil Gelatinase-Associated Lipocalin Receptor as a Novel Partner of CD38 in Chronic Lymphocytic Leukemia: From an Adverse Prognostic Factor to a Potential Pharmacological Target?
Bauvois B; Chapiro E; Quiney C; Maloum K; Susin SA; Nguyen-Khac F
Biomedicines; 2023 Aug; 11(9):. PubMed ID: 37760777
[TBL] [Abstract][Full Text] [Related]
8. Functional impact and molecular binding modes of drugs that target the PI3K isoform p110δ.
Hassenrück F; Farina-Morillas M; Neumann L; Landini F; Blakemore SJ; Rabipour M; Alvarez-Idaboy JR; Pallasch CP; Hallek M; Rebollido-Rios R; Krause G
Commun Biol; 2023 Jun; 6(1):603. PubMed ID: 37277510
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of phosphoinositide 3-kinases delta and gamma reduces chronic B cell activation and autoantibody production in a mouse model of lupus.
Olayinka-Adefemi F; Hou S; Marshall AJ
Front Immunol; 2023; 14():1115244. PubMed ID: 37234154
[TBL] [Abstract][Full Text] [Related]
10. Management of Gastro-Intestinal Toxicity of the Pi3 Kinase Inhibitor: Optimizing Future Dosing Strategies.
Breal C; Beuvon F; de Witasse-Thezy T; Dermine S; Franchi-Rezgui P; Deau-Fisher B; Willems L; Grignano E; Contejean A; Bouscary D; Faillie JL; Treluyer JM; Guerin C; Chouchana L; Vignon M
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190206
[TBL] [Abstract][Full Text] [Related]
11. The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives.
Eyre TA; Riches JC
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174062
[TBL] [Abstract][Full Text] [Related]
12. A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine.
Hermansen JU; Yin Y; Urban A; Myklebust CV; Karlsen L; Melvold K; Tveita AA; Taskén K; Munthe LA; Tjønnfjord GE; Skånland SS
Cell Death Discov; 2023 Apr; 9(1):125. PubMed ID: 37055391
[TBL] [Abstract][Full Text] [Related]
13. Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib.
Till KJ; Abdullah M; Alnassfan T; Janet GZ; Marks T; Coma S; Weaver DT; Pachter JA; Pettitt AR; Slupsky JR
Sci Rep; 2023 Mar; 13(1):3793. PubMed ID: 36882482
[TBL] [Abstract][Full Text] [Related]
14. PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?
Skånland SS; Brown JR
Haematologica; 2023 Jan; 108(1):9-21. PubMed ID: 35899388
[TBL] [Abstract][Full Text] [Related]
15. The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
Lampson BL; Brown JR
Hematol Oncol Clin North Am; 2021 Aug; 35(4):807-826. PubMed ID: 34174987
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
17. Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia.
Patel K; Pagel JM
Curr Hematol Malig Rep; 2019 Aug; 14(4):292-301. PubMed ID: 31203516
[TBL] [Abstract][Full Text] [Related]
18. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
19. Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia.
Witkowska M; Majchrzak A; Robak P; Wolska-Washer A; Robak T
Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):617-633. PubMed ID: 37714711
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
